ISRG

Intuitive Surgical, Inc.

Fundamental data last updated:October 21, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

 


Analyze ISRG on TradingView

VALUATION

P/E

50.07

Market Cap ($M USD)

$148.85B

Forward P/E

24.61

PEG

0.24

PRICE TO SALES

14.07

PRICE TO BOOK

8.54

EV / EBITDA

39.06

5-Year Average P/E

Free Cash Flow Yield

1.90%

DCF Value

$113.65

Graham Number

$96.43

Price to FCF

52.52

EV to FCF

51.80

Earnings Yield

2.00%

FCF Yield

1.90%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$8.39

Next Year EPS Growth Estimate

$17.08

Next Year Revenue Growth Estimate

$18.74B

Return on Equity (ROE)

17.01%

FREE CASH FLOW

Operating Margin

30.45%

Debt-to-Equity

0.02

Piotroski F-Score

8

Altman Z-Score

37.83

Return on Invested Capital (ROIC)

17.71%

Current Ratio

6.03

Quick Ratio

5.01

Net Debt to EBITDA

-0.54

Interest Coverage

0.00

Gross Profit margin

66.29%

FCF PER SHARE

$7.99

REVENUE PER SHARE

$29.82

Analyze ISRG on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be pricing Intuitive Surgical with sky-high expectations, as evidenced by its Price/Earnings ratio of 52.01 and a Forward P/E of 25.57. Despite this, the stock trades significantly above its DCF Value and Graham Number, suggesting a potential overvaluation. However, the Altman Z-score of 39.11 indicates a fortress-like financial stability, while a robust Earnings Yield of 1.92% and a strong ROIC of 17.71% highlight efficient capital use. The market is betting on substantial growth, but the current valuation leaves little room for error.

AI Exposure / Tech Reliance

In the rapidly evolving healthcare sector, Intuitive Surgical is well-positioned to leverage AI and modern technology. As a leader in medical devices, particularly robotic surgery systems, the company is at the forefront of integrating cutting-edge tech into healthcare solutions. This positions them advantageously to adapt and thrive amidst technological shifts.

The Bull Case

For a GARP investor, Intuitive Surgical offers compelling reasons to buy. With a Piotroski F-Score of 8, the company demonstrates strong financial health and operational efficiency. Its impressive ROIC of 17.71% and Operating Margin of 30.45% underscore its pricing power and capital efficiency. Despite a modest FCF Yield of 1.83%, the company's ability to generate cash and reinvest effectively makes it an attractive long-term play.

The Bear Case

Despite its strengths, Intuitive Surgical's valuation metrics raise red flags. The Price/Sales ratio of 14.61 and Price/Book of 8.87 suggest the stock is priced for perfection. The EV to EBITDA ratio of 40.59 further highlights its expensive valuation. Additionally, trading close to its 52-week high with a minimal distance of 4.31% to the low, the stock appears technically overextended, leaving it vulnerable to market corrections.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$607.00

Institutional Ownership %

1-Year Beta

1.51

Insider Buying % (6 Mo)

Distance to 52-Week High

43.68%

Distance to 52-Week Low

1.43%

EARNINGS SURPRISE %

17.92%

50-DAY SMA

$455.01

200-DAY SMA

$495.31

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.